The Role of GLP-1receptor Agonist in Modulating Alcohol Intake: Insides From Semagltide Therapy

Recently, there has been evidence that semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for type 2 diabetes and obesity, may help lower alcohol intake and cravings. Modification of several neurobiological systems that control reward, motivation, and stress reactions is the pharmacological basis for this effect. By inhibiting mesolimbic dopamine signalling, central GLP-1 receptor activation, specifically in the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex, amygdala, and hypothalamus, reduces the reinforcing effects of alcohol. Additionally, semaglutide increases satiety and decreases the motivational salience of alcohol cues by activating the gut–brain axis through vagal afferents. GLP-1R stimulation may also lessen neuroinflammatory processes linked to long-term alcohol exposure and restore normaly to the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Semaglutide and related GLP-1R agonists may be promising pharmacotherapeutic candidates for alcohol use disorder (AUD) because these mechanisms work together to suppress alcohol reward, craving, and stress-induced relapse.